Stockreport

Wave Life Sciences Receives Positive Opinion for Orphan Drug Designation in the European Union for WVE-210201

Wave Life Sciences Ltd. - Ordinary Shares  (WVE) 
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am Check Earnings Report
PDF Investigational WVE-210201 in development for treatment of Duchenne muscular dystrophy patients amenable to exon 51 skipping Patients currently enrolling in global Phas [Read more]